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 Osteoarthritis, or degenerative joint disease, affects over 27 million adults in the 
United States. It is characterized by a net loss of cartilage tissue in the joints, resulting in 
pain, swelling, and loss of mobility. Chondrocytes are the resident cell type of articular 
cartilage, and due to their low mitotic activity and the lack of blood vessels or nerves in the tissue 
in which they reside, cartilage has a limited ability to self-repair. There are currently no approved 
treatments to successfully halt or reverse the progression of the disease. In order to address the 
resulting need for an effective therapeutic, previous work has discovered a novel sugar analog, 
3,4,6-O-Bu3GlcNAc, which has shown the ability to reduce inflammation and increase tissue 
production in an in vitro model of inflammation in animal cells. The following studies seek to 
expand on those results by first showing that the analog is also effective on human cells. When 
the analog was cultured with both human mesenchymal stem cells and human OA chondrocytes 
stimulated by IL-1β to mimic the inflammatory conditions of osteoarthritis, expression of genes 
related to the inflammatory pathway decreased as evaluated by real-time PCR. In addition, genes 
related to the production of the extracellular matrix increased. Thus, we were able to show that 
the analog produced comparable effects in human cells. Subsequent studies focused on 
characterizing the bioenergetics profile of mesenchymal stem cells during differentiation, 
inflammation, and treatment with the sugar analog. It was found that for most conditions, after an 
initial increase, the differentiating cells displayed lower levels of oxygen consumption rates than 
proliferating cells. In monolayer conditions, human and goat MSCs had differing ratios of 
oxidative phosphorylation to glycolysis in the absence of the analog, while the addition of the 
analog eliminated this difference. In three dimensional conditions, except for the unstimulated 
human MSCs, neither inflammation nor the analog produced any significant differences in 
oxygen consumption rates. However, the unstimulated human MSCs did not display the same 
trend and showed an initial difference between the analog-treated and untreated conditions that 
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slowly decreased over the course of differentiation. These results present information that may be 
useful when trying to determine the mechanism of effect of the sugar analog or develop other 
therapeutics for the treatment of the disease. In conclusion, we have shown that the sugar analog 
has comparable effects in human cells that demonstrate that it has the potential to be an effective 
drug candidate for the treatment of osteoarthritis, and furthermore, we have characterized some of 
the metabolic effects of the drug to begin to understand the mechanisms behind its effects or 
possibility to aid in future design. 
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Articular cartilage is a specialized connective tissue found on joint surfaces. Its extracellular 
matrix (ECM) is composed mainly of type II collagen, proteoglycans, and water, containing no 
blood vessels or nerves1. The purpose of this type of cartilage is to provide a lubricated surface 
for the movement of the joint as well as to help transmit loads to the bone underneath for weight 
bearing2. The main cell type found in this tissue, the chondrocyte, is responsible for producing 
and maintaining the ECM. However, its low mitotic activity, coupled with the tissue’s avascular 
nature, results in the limited ability of the cartilage to self-repair3.  
This limited self-reparability presents an issue when the cartilage is damaged or worn down 
as seen in osteoarthritis (OA). OA, or degenerative joint disease, results in the net loss of the 
articular cartilage due to an imbalance between the production and degradation of the cartilage 
ECM. This disease leads to an increase in inflammatory molecules that stimulate improper repair, 
which results in joint swelling, pain, and limited mobility for the patient due to loss of proper 
joint function4. There are over 27 million people in the U.S. alone who are diagnosed with OA, 
making this an important area of research5. 
Currently, the exact causes of OA are poorly understood, and there is no treatment that can 
completely halt or reverse the progression of the disease6. Instead, current treatments mainly 
focus on treating the symptoms of OA. Patients are given a variety of analgesics and steroidal or 
viscosupplement injections to manage the pain and symptoms. However, in some cases, they may 
have to resort to surgery or total knee replacements if the disease has progressed beyond 
treatment. This is costly and undesirable for a variety of reasons, leading to a significant need for 
a therapy that can stop or reverse the progression of OA7,8. 
A suitable therapeutic for the treatment of OA would need to both reduce or eliminate the 
inflammation provoked by the disease as well as promote cartilage repair by increasing 
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production of the ECM. The inflammation in OA is believed to be triggered by the release of pro-
inflammatory cytokines, IL-1β and TNFα. These cytokines activate the NFκB pathway within the 
cell that leads to the production of matrix metalloproteinases (MMPs) and a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS), which degrade collagen and 
aggrecan, respectively. NFκB also upregulates the production of the pro-inflammatory cytokines 
and other molecules that continue this feedforward inflammatory cycle9,10.  
Previous work has demonstrated the ability of a novel sugar analog, 3,4,6-O-Bu3GlcNAc, to 
achieve both anti-inflammatory and ECM producing effects in bovine cells in vitro7. Before a 
drug candidate can move forward to clinical trials, it must pass rigorous animal tests. It would be 
a waste of resources to apply the analog to animal studies if the outcome was that, despite initial 
successes, it would be impossible to implement in humans. Therefore, it is important to also 
verify whether these effects can be seen in human cells. 
In addition to testing the analog with human cells, another important aspect is to examine its 
potential role in the modulation of cell metabolism. While the effects of the analog have 
previously been studied, the mechanisms behind its effects are still not clear. Perhaps probing 
metabolism, specifically looking at pathways related to the cells’ oxygen consumption, might 
provide some insight into the way the analog produces its effects within the cell. This could in 
turn to lead to information that could enhance its use or lead to the discovery of other compounds 
that could produce the same or increased effects. 
The rest of this work describes these studies in further detail. In Chapter 2, the analog’s 
effects on human cells are explored, with respect to inflammation and ECM production. In 
Chapter 3, the analog’s effects on metabolism are explored, with respect to the balance between 






Osteoarthritis is a disease of the joint, characterized by loss of cartilage tissue, increased 
inflammation, and the resulting swelling, pain, and disability. There are currently no approved 
treatments that completely halt or reverse the progression of the disease; instead, current 
therapeutic strategies only mitigate pain and the symptoms of the disease. With over 27 million 
adults affected by osteoarthritis in the United States alone, there is a great need for the 
development of a more effective therapy4,5. 
Previous work by Coburn et al. has shown the potential of a novel sugar analog, 3,4,6-O-
Bu3GlcNAc, as a possible drug candidate for the treatment of osteoarthritis. Their work 
demonstrates the ability of the analog to both reduce inflammation and increase extracellular 
matrix production in animal cells in an in vitro model of the disease7.  
Inflammation in osteoarthritis is believed to play a major role in the progression of the 
disease and the resulting imbalance between the production and degradation of the ECM. The 
NFκB pathway is initiated by the inflammatory cytokines, IL-1β and to a lesser extent TNFα, 
which are found in the joint space in osteoarthritic patients, secreted by the synovial cells that line 
the joint. NFκB transcriptionally regulates the expression of matrix metalloproteinases (MMPs), a 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and other pro-
inflammatory cytokines and transcription factors. These collectively lead to the breakdown of the 
matrix components as well as continued inflammation, leading to further increases in the 
production of these catabolic enzymes9. 
3,4,6-O-Bu3GlcNAc has been shown to decrease the expression of genes associated with the 
NFκB pathway in IL-1β-stimulated bovine chondroctyes as an in vitro model of osteoarthritis. 
The analog has also been shown to increase the expression of genes that lead to increased ECM 
production, supported by increased histological and immunostaining of cartilage ECM 
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components such as proteoglycans and collagen II, respectively7. While this is promising for the 
future of the analog as a novel drug candidate for the treatment of osteoarthritis, it is important to 
demonstrate that its anti-inflammatory properties are also capable of treating human cells. 
In the following work, we show that 3,4,6-O-Bu3GlcNAc has comparable anti-inflammatory, 
matrix-producing effects in both human mesenchymal stem cells and human chondrocytes 
harvested from osteoarthritic tissue. The analog decreases the expression of genes associated with 
the NFκB pathway in both cell types, in monolayer and in three dimensional PEGDA hydrogels. 
The analog also increases the expression of genes associated with matrix production in both cell 
types in the three dimensional environment. From this, we conclude that the analog demonstrates 
the same potential to downregulate important inflammatory pathways in the progression of 
osteoarthritis for human cells.  
 
2.2. Materials and methods 
2.2.1. Synthesis of the novel sugar analogs 
3,4,6-O-Bu3GlcNAc was synthesized by the Yarema lab as previously described, lyophilized, 
and stored at -20°C11. Stock solutions were prepared by dissolving the analog in 100% EtOH. The 
analog solution was stored at 4°C prior to use. The chemical structure of 3,4,6-O-Bu3GlcNAc is 
shown in Figure 2.1 A. 
 
2.2.2. Cell harvesting and culture 
Passage 1 human MSCs (hMSCs) were obtained from the Caplan Lab, Case Western Reserve 
University, and stored in liquid nitrogen until required for experiments. After thawing, cells were 
cultured in low glucose Dulbecco’s modified eagles medium (DMEM) containing 10% fetal 
bovine serum (FBS) from a lot specified by the Caplan Lab as suitable for human MSCs, 2 mM 
L-glutamine, 100 μg/mL penicillin/streptomycin, and 8 ng/mL fibroblast growth factor (bFGF). 
The cells were passaged once for stabilization before culturing in experimental conditions.  
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Human osteoarthritic (hOA) cartilage samples were obtained from National Disease Research 
Interchange donors, three males ages 66-77 who underwent knee replacement for osteoarthritis 
treatment. The cartilage tissue was sliced away from the underlying bone and cut into small 
pieces no more than 1 mm3 in size. The tissue pieces were digested overnight at 37°C on an 
orbital shaker in 0.05% type II collagenase solution with high glucose DMEM. Following 
digestion, the solution was passed through a 70 μm cell strainer and centrifuged to form a 
cell pellet. The collagenase solution was aspirated and the pellet was washed in sterile 
phosphate buffered saline (PBS) with 100 μg/mL penicillin/streptomycin. The suspension 
was centrifuged, the PBS aspirated, and the cells resuspended in fresh PBS and 
penicillin/streptomycin. This was repeated for a total of three washes. The cells were then 
cultured at 37°C in a 5% CO2 incubator in media composed of high glucose DMEM, 
10% FBS, 10 mM HEPES, 10 mM sodium pyruvate, 0.1 mM non-essential amino acids, 
0.4 mM L-proline, 50 μg/ml ascorbic acid, and 100 μg/mL penicillin/streptomycin. 
 
2.2.3. Monolayer experiment 
The monolayer experiment was performed with the hMSCs. The cells were initially cultured 
as previously described. After ten days, cells were trypsinized, centrifuged, and resuspended in 
fresh media before being plated in a 24-well plate at 50,000 cells/well. For the first 24 hours, the 
hMSCs were incubated in the presence or absence of 10 ng/mL IL-1β. At the end of this period, 
the media was replaced with fresh media containing 0 μM or 100 μM 3,4,6-O-Bu3GlcNAc with 
the respective IL-1β concentration for another 24 hours. 
 
2.2.4. PEGDA hydrogel experiment 
The three dimensional experiment was carried out with both hMSCs and hOA chondrocytes. 
First, the polymer solution was prepared by dissolving 100 mg poly(ethylene glyocol)-
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diacrylate (PEGDA) in 1 mL sterile PBS. The photoinitiator solution was prepared by 
dissolving 100 mg Irgacure 2959® in 1 mL of 70% EtOH, and then 5 μL of the 
photoinitiator solution was added to the polymer solution and kept on ice. Cells were trypsinized, 
centrifuged, and resuspended in the PEGDA+photoinitiator solution, and 20 μL of this cell 
suspension was transferred into cylindrical molds. Crosslinking was initiated by exposing the 
solution in the molds to UV-A light (365 nm, 3.2 mW/cm2) for 5 minutes. The newly formed 
hydrogels were transferred into 24-well plates and cultured in 2 mL of chondrogenic media (high 
glucose DMEM, 100 μg/mL penicillin/streptomycin, 10 mM sodium pyruvate, 100 nM 
dexamethasone, 5 mL insulin/transferrin/selenous acid (ITS), 40 μg/mL L-proline, 50 μg/mL 
ascorbic acid, and 10 μL/mL TGFβ1) in the presence or absence of 10 ng/mL IL-1β for the first 
three days. Then, media was replaced with fresh media containing 0 μM or 100 μM 3,4,6-O-
Bu3GlcNAc with the respective IL-1β concentration for an additional 18 days, with the media 
changed every 2-3 days. 
 
2.2.5. Gene expression 
RNA was extracted from the cultures and constructs with Trizol and reverse transcribed to 
cDNA with SuperScript™ II reverse transcriptase following an established protocol. Real-
time PCR reactions were carried out using the StepOnePlus™ Real Time PCR System, 
with all genes normalized to GAPDH and expression levels calculated using the 2-ΔΔCt 
method in Excel12. The primers used are listed in Table 2.1. 
 
2.2.6. Statistical analysis 
Data are shown in Figures 2.2-2.4 as mean + standard deviation. Significance was 






2.3.1. The effect of 3,4,6-O-Bu3GlcNAc on NFκB target genes in human MSCs in monolayer 
To determine the effect of the sugar analog on human MSCs, the cells were first cultured with 
or without IL-1β to activate the NFκB pathway for 24 hours in monolayer. The cells were then 
exposed to either 0 μM or 100 μM 3,4,6-O-Bu3GlcNAc, the most effective concentration found 
from previous studies7, with their respective IL-1β concentrations for an additional 24 hours 
(Figure 2.1 B). Genes that are relevant to the inflammatory pathway activated by NFκB were 
then evaluated by real time PCR, which included NFκB1, IκBα, MMP13, and iNOS. After the 
48-hour period, cells which were cultured in the presence of IL-1β alone all showed an increase 
in the expression of these four genes. IL-1β-stimulated cells that were then treated with the sugar 
analog showed a significant decrease in the expression of all four of these genes. Cells that were 
not stimulated with IL-1β but were exposed to the analog showed no significant change in the 
expression level of these genes (Figure 2.2). 
 
2.3.2. Comparing the effects of 3,4,6-O-Bu3GlcNAc on NFκB target genes in human MSCs and 
OA chondrocytes in 3D 
To compare the effects of the sugar analog on MSCs and chondrocytes, the cells were 
encapsulated in PEGDA hydrogels and cultured with or without IL-1β for the first 3 days. The 
cells were then cultured in media containing 0 μM or 100 μM 3,4,6-O-Bu3GlcNAc with their 
respective IL-1β concentrations for an additional 18 days to allow for chondrogenic 
differentiation (Figure 2.1 B). Changes in the levels of expression for pro-inflammatory genes 
MMP13 and NFκB1 were then evaluated using real time PCR. After the 3-week period, both 
MSCs and OA chondrocytes showed an increase in the expression of these genes in the presence 
of IL-1β without addition of the sugar analog, similar to the results of the monolayer study. In the 
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IL-1β-stimulated cells treated with the analog, the expression of these genes decreased relative to 
the untreated, stimulated cells. Both cell types showed a comparable level of decrease in 
expression of these two genes (Figure 2.3). 
 
2.3.3. Comparing the effect of 3,4,6-O-Bu3GlcNAc on chondrogenic genes in human MSCs and 
OA chondrocytes in 3D 
The effect of the sugar analog on the chondrogenic gene expression of human MSCs and OA 
chondrocytes was also studied at the end of the 3-week three dimensional experiment. 
Specifically, changes in expression of genes for type II collagen and aggrecan were studied using 
real-time PCR. For OA chondrocytes, the cells cultured in the presence of IL-1β without the 
addition of the sugar analog showed a decrease in the expression of these genes, while the same 
trend was not observed in the human MSCs. Both cell types showed an increase in the expression 
of these genes after treatment of the analog to the IL-1β-stimulated cells as compared to the 
stimulated but untreated cells. For the OA chondrocytes, this increase in expression of these 
genes brought the expression levels back to be comparable to the control, while in the hMSCs the 
increased level was greater than that of the control (Figure 2.4). 
2.4. Discussion 
Osteoarthritis of the knee results in the loss of cartilage tissue and increased inflammation in 
the joint space that leads to further degeneration, pain, and loss of mobility. Currently there are no 
approved treatments that can completely halt or reverse the progression of this disease. Previous 
work by Coburn et al. has shown that a novel sugar analog, 3,4,6-O-Bu3GlcNAc, can reduce 
inflammation by reducing NFκB activity and increase ECM accumulation in IL-1β-stimulated 
bovine chondrocytes. This work expands on the previous study by applying the sugar analogs to 
9 
 
human cells, both mesenchymal stem cells and OA chondrocytes, to examine whether the analog 
is just as effective in reducing inflammation and stimulating chondrogenesis in these cells. 
Mesenchymal stem cells have the ability to differentiate into various cell types, including 
chondrocytes. To compare the sugar analog’s effect on human cells to that found in the previous 
work, we first applied the analog in a short term, monolayer model of inflammation with human 
MSCs. IL-1β was used to stimulate inflammation by activating the NFκB pathway13. In the 
MSCs, it was found that stimulating the cells with IL-1β over a period of 48 hours upregulated 
several genes associated with the inflammatory pathway: NFκB1, IκBα, MMP13, iNOS. In the 
cells that were also treated with the analog, these genes were significantly downregulated 
compared to the stimulated, untreated condition. The analog alone did not change the expression 
of these genes in the human MSCs. These results indicate in 2D cell culture conditions human 
cells will respond to the analog in the same way as animal cells. However, because a three 
dimensional environment is more appropriate to mimic in vivo conditions, both human MSCs and 
chondrocytes were tested in a 3D model to confirm the analog’s effects14. 
PEGDA hydrogels have been previously shown to support chondrocyte growth and maintain 
their differentiated phenotype15. Human MSCs and OA chondrocytes were selected for the three 
dimensional study, the latter in particular to obtain the closest possible in vitro model of the 
disease. With both cell types, we found that the cells stimulated with IL-1β showed increased 
expression of the inflammatory genes NFκB1 and MMP13, while treatment with the analog after 
stimulation decreased the expression of these genes. The stimulated hMSCs showed a greater 
fold-change increase in the expression of MMP13 than the OA chondrocytes, but the fold-change 
decrease after the addition of the analog was more similar between the two cell types. This 
confirmed the results found in the monolayer study. To corroborate the inflammatory results, the 
analog’s effects on chondrogenic genes was also studied. We found that treating the cells with the 
sugar analog after IL-1β stimulation increased the expression of genes for type II collagen and 
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aggrecan. These results show support for the sugar analog being an acceptable drug candidate in 
human cells.  
In conclusion, while previous work has shown that the analog has the ability to reduce 
inflammation and increase chondrogenesis in bovine chondrocytes, this work is the first to show 
that the analog is comparably effective in human cells, specifically MSCs and OA chondrocytes. 
The limitation of this work is that it is only an in vitro model. The next steps are to study the 






Table 2.1. List of primers used for real-time PCR  
Gene Sequence 
  
NFκB F - CTGGAAGCACGAATGACAGA 
R –CCTTCTGCTTGCAAATAGGC 
 
IκB F - GCTGATGTCAATGCTCAGGA 
R – CCCCACACTTCAACAGGAGT 
 
MMP13 F - TTGAGCTGGACTCATTGTCG 
R – CGCGAGATTTGTAGGATGGT 
 
iNOS F - AGGGAGTGTTGTTCCAGGTG 
R – TCTGCAGGATGTCTTGAACG 
 
Type II Collagen F - CGCCGCTGTCCTTCGGTGTC 
R – AGGGCTCCGGCTTCCACACAT 
 
Aggrecan F - TGGGAACCAGCCTATACCCCAG 
R – CAGTTGCAGAAGGGCCTTCTGTAC 
 
GAPDH F - TGAAGGTCGGAGTCAACGGATTTGGT 
R – CATGTGGGCCATGAGGTCCACCAC 
 
Beta Actin F - GCTCCTCCTGAGCGCAAGTAC 







Figure 2.1.    (A) Structure of 3,4,6-O-Bu3GlcNAc and (B) experiment timelines for both 
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Figure 2.2.    Anti-inflammatory effects of 3,4,6-O-Bu3GlcNAc on unstimulated and IL-1β-
stimulated human MSCs after 48 hours in monolayer, as shown by changes in gene expression of 
targets of the NFκB inflammatory pathway. Data presented as mean and SD of 3 independent 
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Figure 2.3.    Anti-inflammatory effects of 3,4,6-O-Bu3GlcNAc on unstimulated and IL-1β-
stimulated (A) human MSCs and (B) human OA chondrocytes, after 3 weeks in PEGDA 
hydrogels, as shown by changes in gene expression of targets of the NFκB inflammatory 
pathway. Data presented as mean and SD of 3 independent samples for each condition. ( * 
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Figure 2.4.    Effects of 3,4,6-O-Bu3GlcNAc on unstimulated and IL-1β-stimulated (A) human 
MSCs and (B) human OA chondrocytes, after 3 weeks in PEGDA hydrogels, as shown by 
changes in gene expression of ECM markers, type II collagen and aggrecan. Data presented as 















3.1. Introduction  
Metabolism describes all the processes in the body that are responsible for using or 
converting energy into different forms. Cell metabolism focuses on these processes within 
individual cell, including cellular respiration. In tissue engineering, so much emphasis has been 
placed on developing appropriate scaffolds, directing stem cells, and studying appropriate 
biological cues, that not as much focus has been directed towards studying the role of metabolism 
in this field. It is important to explore the effects of diseases such as osteoarthritis on aspects of 
metabolism within the affected cells, for modulating such processes may lead to unique pathways 
for effective therapy16. 
There are a number of different metabolic pathways and products that may influence tissue 
production and repair; the focus of this work will be on the balance of glycolysis and oxidative 
phosphorylation in particular. A cell uses both of these processes in order to generate energy in 
the form of ATP. Sometimes certain factors cause the cell to switch to predominately relying on 
one or the other for a majority of its ATP production. Such is the case in the phenomenon known 
as the Warburg effect observed in cancer cells that switch to utilizing higher levels of 
glycolysis17. Proliferating cells have been observed to make the opposite switch, from mainly 
glycolysis to higher levels of oxidative phosphorylation, when they start to differentiate18.  
Reid et al. showed that consistent with this previous property of differentiating cells, 
mesenchymal stem cells that were differentiating towards both adipogenic and osteogenic 
lineages showed an increase in utilizing oxidative phosphorylation relative to glycolysis. 
However, in the literature, it has been shown that MSCs differentiating toward a chondrogenic 
lineage show the opposite effect by increasing glycolysis, contradicting generalizations about 
differentiating cells19. The effects of inflammation on mitochondrial metabolism also seem to be 
varied. While baseline NFκB activity has been shown to promote an increase in the use of 
oxidative phosphorylation, excessive activity leads to the downregulation of genes that code for 
17 
 
proteins in the electron transport chain in the mitochondria, leaving the cell to be more dependent 
on glycolysis20,21.  
In this work, we seek to characterize the bioenergetic profile of mesenchymal stem cells as 
they undergo chondrogenic differentiation. In addition to determining the effect of this 
differentiation on their metabolism, we also will show how stimulating the cells with IL-1β to 
produce an inflammatory state will affect their usage of oxidative phosphorylation and glycolysis, 
and how that changes after the addition of the sugar analog 3,4,6-O-Bu3GlcNAc that has been 
shown to decrease inflammation through inhibiting NFκB activity. 
 
3.2. Materials and methods 
3.2.1. Synthesis of the novel sugar analogs 
3,4,6-O-Bu3GlcNAc was synthesized by the Yarema lab as previously described, lyophilized, 
and stored at -20°C. Stock solutions were prepared by dissolving the analog in 100% EtOH and 
stored at 4°C prior to use. The chemical structure of 3,4,6-O-Bu3GlcNAc is shown in the previous 
chapter in Figure 2.1 A. 
 
3.2.2. Cell culture 
Passage 2-4 human MSCs were thawed from storage after the experiments in Chapter 2, 
initially obtained from the Caplan group (Location). The cells were cultured in low glucose 
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 μg/mL penicillin/streptomycin, 
and 8 ng/mL bFGF, and passaged once for stabilization prior to experiments. Passage 2-4 goat 
MSCs were thawed from liquid nitrogen storage, initially isolated as previously described. The 
cells were cultured in high glucose DMEM supplemented with 10% FBS, 2 mM L-glutamine, 
100 μg/mL penicillin/streptomycin, and 8 ng/mL bFGF, and also passaged once for stabilization 




3.2.3. Monolayer and three dimensional experiments 
For the monolayer experiment, cells were trypsinized, centrifuged, and resuspended in fresh 
media before being plated in a Seahorse V7 24-well plate at 50,000 cells/well. For the first 24 
hours, the MSCs were incubated in the presence or absence of 10 ng/mL IL-1β. At the end of this 
period, the media was replaced with fresh media containing 0 μM or 100 μM 3,4,6-O-Bu3GlcNAc 
with the respective IL-1β concentration for another 24 hours. For the three dimensional 
experiment, first the polymer solution was prepared by dissolving 100 mg PEGDA in 1 mL 
sterile PBS. The photoinitiator solution was prepared by dissolving 100 mg Irgacure 
2959® in 1 mL 70% EtOH, and then 5 μL of the photoinitiator solution was added to the 
polymer solution and kept on ice. Cells were trypsinized, centrifuged, and resuspended in the 
PEGDA+photoinitiator solution, and 20 μL of this cell suspension was transferred into cylindrical 
molds. Crosslinking was initiated by exposing the solution in the molds to UV-A light (365 nm, 
3.2 mW/cm2) for 5 minutes. The newly formed hydrogels were transferred into 24-well plates 
and cultured in 2 mL chondrogenic media in the presence or absence of 10 ng/mL IL-1β for the 
first three days. Then, media was replaced with fresh media containing 0 μM or 100 μM 3,4,6-O-
Bu3GlcNAc with the respective IL-1β concentration for an additional 18 days, with the media 
changed every 2-3 days. 
 
3.2.4. Bioenergetics experiments 
Bioenergetics experiments were performed using the Seahorse Bioscience XF24 Instrument. 
This instrument measures the rate of oxygen consumption and extracellular acidification by 
measuring O2 content and pH in each well, respectively. Different compounds can be injected 
through four ports in the specialized sensor cartridge loaded with each assay plate, and mixing 
and measuring times can be set in the machine protocol. Before each assay, the sensor cartridge 
must be hydrated for at least four hours in 1 mL of Seahorse XF calibrant solution. 
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For the monolayer bioenergetics measurements, prior to the start of the assay, the cells were 
washed three times with non-buffered, glucose-supplemented DMEM and allowed to incubate in 
500 μL of this media for 45 minutes. During this time, the sensor cartridge was loaded into the 
machine along with a 24-well plate containing the calibrant solution for calibration. At the end of 
calibration, the cell-seeded plate was transferred into the machine and the program was allowed 
to run. At the end of the run, the cells were taken out, washed thrice with sterile PBS, and fixed 
with 10% formalin for 10 minutes and stored at 4°C until needed for the DNA assay. 
A similar protocol was followed for the three dimensional bioenergetics measurements. Cell-
laden gels were transferred to a special islet capture microplate on the morning of the experiment 
after three washes with special non-buffered, glucose-supplemented DMEM. The gels were 
allowed to incubate in this media for 45 minutes while the sensor cartridge was calibrated. After 
calibration, the plate was transferred into the machine. At the end of the experiment, the gels were 
washed three times with sterile PBS, soaked in 10% formalin for 20 minutes, and stored at 4°C 
for use in the DNA assay. 
 
3.2.5. DNA assay for data normalization 
To normalize the results from the Seahorse bioenergetics experiments, a DNA assay was 
performed using a modified PicoGreen dsDNA reagent protocol. For the monolayer experiment, 
the cell layer was washed once with PBS and then incubated with a lysing solution containing 
250 μL of 10 mM Tris, 1 mM EDTA, 0.1% Triton X-100, and 0.1 mg/mL Proteinase K in a warm 
water bath for 10 minutes. For the three dimensional experiment, the hydrogels were first 
lyophilized for 48 hours and then homogenized after the addition of 250 μL of the lysing solution. 
The samples were then transferred to fresh microcentrifuge tubes and placed on a heating block at 
60°C overnight. The next morning, they were transferred to 4°C storage prior to experiments.  
For the next part of the assay, 20x TE buffer stock was prepared with a final concentration of 
200 mM Tris-HCl and 20 mM EDTA in sterile ddH2O, adjusted to a pH of 7.5, and stored in -
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20°C. Prior to experiments, a small amount of this 20x buffer was diluted with sterile ddH2O to 
make 1x TE buffer. The PicoGreen working solution was prepared by diluting the PicoGreen 
reagent 200-fold in 1xTE. Samples were brought to room temperature and diluted 1:100 with 1x 
TE buffer to ensure that their DNA content fell within the working range of the PicoGreen 
reagent. Standards were made by diluting 100 μg/mL calf thymus DNA stock to a working 
concentration of 2 μg/mL in 1xTE, and then further diluting to various concentrations within 0-
1000 ng/mL. 100 μL of each of the samples and standards was added to a black 96-well plate in 
duplicate, with 100 μL of PicoGreen added to each well. The plate was incubated for five minutes 
at room temperature before fluorescence was measured using a microplate reader (480 nm/520 
nm). Cell counts were calculated in Excel using the following equation and dividing by the 
amount of DNA per cell found by repeating the DNA assay on a fixed number of cells to obtain 
an average DNA/cell value: 
𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 (𝑛𝑔) = (
𝐹
𝑠𝑙𝑜𝑝𝑒





3.2.6. Statistical analysis 
Data are shown in Figures 3.1-3.3 as mean + standard deviation. Significance was 
determined by student’s t-test computed in Excel for P < 0.05. 
 
3.3. Results 
3.3.1. Comparing the effect of 3,4,6-O-Bu3GlcNAc on metabolism in goat and human MSCs in 
monolayer 
To determine the effects of the sugar analog on oxygen consumption rates (OCR) and 
extracellular acidification rates (ECAR), which provide information about oxidative 
phosphorylation and glycolysis, respectively, the MSCs were first cultured with or without IL-1β 
for 24 hours in monolayer. The cells were then exposed to either 0 μM or 100 μM 3,4,6-O-
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Bu3GlcNAc with their respective IL-1β concentrations for an additional 24 hours. The cells were 
then analyzed using the Seahorse XF24 analyzer to measure their metabolic activity. After the 48-
hour period, unstimulated and stimulated human MSCs that were cultured without the sugar 
analog had a higher ratio of oxidative phosphorylation to glycolysis compared to goat MSCs 
cultured in the same conditions. When both cell types were cultured in the presence of the analog 
with or without IL-1β stimulation, their OCR/ECAR ratios became more equal (Figure 3.1A).  
 
3.3.2. Comparing the effect of 3,4,6-O-Bu3GlcNAc on metabolism between monolayer and three 
dimensional studies with human MSCs 
To study the differences in the effects of the sugar analog on OCR between monolayer and 
three dimensional studies, human MSCs were first stimulated with IL-1β for 3 days in both 
experimental conditions. The cells were then exposed to either 0 μM or 100 μM 3,4,6-O-
Bu3GlcNAc with their respective IL-1β concentrations for an additional 4 days. The cells were 
then analyzed using the Seahorse XF24 analyzer to measure their metabolic activity. After the 1-
week period, both 2D- and 3D-cultured cells showed similar OCR values for all conditions, with 
the exception of the unstimulated cells exposed to the sugar analog. These cells had a higher OCR 
value in monolayer than they did in the three dimensional study (Figure 3.1B).  
 
3.3.3. The effect of 3,4,6-O-Bu3GlcNAc on metabolism during chondrogenic differentiation of 
human and goat MSCs 
To examine the changes in OCR over the course of chondrogenic differentiation as well as 
the effect of inflammation and the sugar analog on this change, human and goat MSCs were 
encapsulated in PEGDA hydrogels and cultured in chondrogenic media for three weeks. During 
the first three days, the cells were exposed to 0 or 10 ng/mL IL-1β, and then for the rest of the 
three weeks, exposed to 0 μM or 100 μM 3,4,6-O-Bu3GlcNAc with their respective IL-1β 
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concentrations. The cells were then analyzed using the Seahorse XF24 analyzer to measure their 
metabolic activity. For both cells in all of the four conditions, OCR decreased between 1 week 
and 3 weeks of differentiation (Figure 3.2). A time course of the effect of the sugar analog was 
plotted over the 3 weeks. The general trend was the same for both stimulated and unstimulated 
goat cells. The OCR initially increased up to the 1 week point, and then decreased to below the 
initial value after 3 weeks. The trend was different for human cells. The unstimulated cells 
continued to have decreasing OCR throughout the differentiation period, while the stimulated 
cells followed the previous trend. For the unstimulated cells, the human MSCs initially had 
different OCR values for the untreated and treated cells which later converged to the same value. 
For the goat cells, it was the opposite, with the values initially the same and then diverging. 
3.4. Discussion 
In the fields of tissue engineering and regenerative medicine, metabolism is gaining 
popularity as an avenue of exploration for new ways to manipulate tissue production and repair. 
The intersection of the study of metabolism and inflammation may also have interesting 
implications for tissue repair.  
It has been shown in the literature that proliferating and differentiating cells have contrasting 
mitochondrial metabolism: proliferating cells prefer to utilize predominately anaerobic glycolysis, 
while differentiating cells prefer to rely on oxidative phosphorylation. Reid et al. supported this in 
his work that found that both osteogenic and adipogenic differentiation caused a shift to a more 
oxidative energy metabolism. In the literature, however, it has also been discovered that 
chondrogenic differentiation is different from those other lineages. Since chondrogenesis is 
relevant for the repair of cartilage tissue, we studied the metabolic effects of this differentiation in 
the current work. It is important to connect the metabolic effects of differentiation with the effects 
of inflammation as well as the novel sugar analog, whose effects on metabolism have never been 
tested. Knowing the basic effects these factors have on the balance between oxidative 
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phosphorylation and glycolysis may give insight into the way they affect differentiation and 
tissue production. 
The experimental setup used in these studies were as described in Chapter 2. It was found that 
human and goat MSCs cultured in monolayer behaved similarly in terms of the ratio of oxygen 
consumption rate (OCR) to extracellular acidification rate (ECAR) after being subjected to the 
sugar analog. This indicates that the analog produces a uniform balance between the utilization of 
oxidative phosphorylation and glycolysis across both cell types. A pattern of difference between 
cells cultured in monolayer and cells cultured in three dimensional constructs was less 
discernable. Cells cultured with the analog alone had a difference in behavior, with monolayer 
cultures showing a higher oxygen consumption rate than three dimensional cultures, but the rest 
of the conditions did not display significant differences.  
Supporting the conclusions from the literature about chondrogenesis, the three dimensional 
experiments verified that both human and goat cells have lower OCR values after differentiation. 
While that does not seem to support the evidence that differentiating cells usually have a higher 
dependence on oxidative phosphorylation, the reason for this behavior in chondrocytes could be 
due to the cells adapting the avascular environment of cartilage tissue. The time course graphs do 
reveal more about what may be happening with the balance of these two metabolic processes. 
Most conditions show an increase in oxygen consumption after one week of differentiating, and 
only then a decrease in OCR as differentiation continues. It is possible that the initial rise in OCR 
values accounts for the higher oxidative phosphorylation that occurs in differentiating cells which 
is not normally seen at the end of chondrogenic differentiation. Meanwhile, when comparing all 
graphs, stimulating the cells with IL-1β does not seem to have much of an effect on oxygen 
consumption or the ratio of the two processes.  
In conclusion, we found evidence of specific metabolic changes that occur over the course of 
chondrogenic differentiation. While stimulating inflammation with IL-1β did not seem to have 
much of an effect on these specific metabolic processes, it is possible that it has other effects on 
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processes that were not studied in this work. The analog seems to have the most effect on cells in 
monolayer and unstimulated cells in hydrogels. In monolayer, it equalizes the balance between 
the primary utilization of oxidative phosphorylation and glycolysis, while in the three 
dimensional study, it seems to have opposite effects on human and goat cells. This shows that 
some attention may need to be paid to the different effects the analog has on human and animal 
cells, and further studies of different metabolic processes may help discover more about its 
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Figure 3.1.    Comparison of the metabolic effects of 3,4,6-O-Bu3GlcNAc on (A) unstimulated and 
IL-1β-stimulated human and goat MSCs in a monolayer study and (B) unstimulated and IL-1β-
stimulated human MSCs in both the monolayer and three dimensional study. Data presented as 
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Figure 3.2.    Effects of 3,4,6-O-Bu3GlcNAc on unstimulated and IL-1β-stimulated human and goat 
MSCs undergoing chondrogenic differentiation, as shown by changes in oxygen consumption rates 
between 1 week and 3 weeks after encapsulation in PEGDA hydrogel constructs. Data presented 
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Figure 3.3.    Time course of the effects of 3,4,6-O-Bu3GlcNAc (“Analog”) on (A) unstimulated 
and (B) IL-1β-stimulated, human and goat MSCs undergoing chondrogenic differentiation, as 
shown by changes in oxygen consumption rates. Data presented as mean and SD of 4 independent 







This work examined the effects of the sugar analog 3,4,6-O-Bu3GlcNAc on inflammation and 
metabolism in human cells, specifically mesenchymal stem cells and osteoarthritic chondrocytes. 
It was found that the analog decreases the expression of genes associated with the inflammatory 
pathway implicated in the progression of osteoarthritis while also upregulating the expression of 
genes associated with the production of the cartilage extracellular matrix in both cell types. The 
analysis of cellular oxygen consumption shows an overall decrease as is consistent with the 
literature on the effects of chondrogenesis on the balance of oxidative phosphorylation and 
glycolysis. However, the effect of the sugar analog on this balance, or on the cells’ oxygen 
consumption alone, are not clear. The analog appears to have an equalizing effect between human 
and goat cells in monolayer, acting oppositely on each cell type so that they both end up with the 
same OCR/ECAR ratio. In human MSCs, IL-1β stimulated cells treated with the analog showed 
no differences in oxygen consumption when compared to untreated cells. The unstimulated cells 
showed an initial difference which eventually disappeared after the 3-week period. In this 
condition, it may be said that again the analog plays an “equalizing” role. 
The implications of these results may be unclear because metabolism encompasses a broad 
spectrum of processes, of which only one small part was studied in this work. This limitation 
makes drawing a completely conclusion difficult, but this data paints a preliminary picture of 
what might be happening in the cell and may guide future experiments. A goal for future work 
would be to examine other metabolic pathways that may be affected by the analog to uncover 
more about its mechanisms. Another important point of future work would be to take the results 
from the inflammation study and proceed to animal studies to determine the effectiveness of the 
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